Contact : +34 91 452 49 41 | info@algenex.es
Algenex Alternative Gene Expression
About us
ALGENEX is a biotechnology company focused on development of recombinant products and technologies to improve Human and Animal Health. We develop recombinant vaccines, diagnostic and therapeutic molecules, eliminating the costly process of fermentation through efficient use of insects as small live bioreactors.
Technology
ALGENEX has proprietary platform technologies to improve recombinant protein production and vaccines efficacy, as well as well differentiated products in the field of vaccines, diagnostic and therapeutic molecules. IBES® technology, APCH1 “inteligent” adjuvant or Top-Bac baculoviruses represent breakthrough developments for the pharmaceutical industry.
Business model
Our business model contemplates alliances and joint ventures with companies that have the capability and interest in co-development of new products and/or have the regional or global market presence to successfully promote our products.
Our Compromise
ALGENEX was created to connect research and application as straightforwardly and time-efficiently as possible. We consider that helping underprivileged societies, through major cost reduction, to gain access to technological products that will improve their health and their economy, is our contribution to society.
ALGENEX portfolio of platforms and products
Publications
- B. Hernáez et al. (2010).Small peptide inhibitors disrupt a high-affinity interaction between cytoplasmic dynein and a viral cargo protein. Journal of Virology 84.10792-10801
- F. Gil et al. (2010). Targeting antigens to an invariant epitope of the MHC Class II DR molecule potentiates the immune response to subunit vaccines. Virus Research (in press)
- A.F. Millán et al. (2010). Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva. Protein Expr Purif. 74:1-8
- E Pérez-Marín et al. (2010). Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae Vaccine 28:2340-2349
- F. Todolí et al. (2010). Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs. American Journal of Tropical Medicine & Hygiene 82:795-800